7,183 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Acquired by Hanseatic Management Services Inc.

Hanseatic Management Services Inc. acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 7,183 shares of the company’s stock, valued at approximately $258,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DYN. Nisa Investment Advisors LLC grew its position in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the period. US Bancorp DE raised its position in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Dyne Therapeutics during the 3rd quarter worth $62,000. Amalgamated Bank lifted its holdings in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Dyne Therapeutics by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after purchasing an additional 709 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Up 4.2 %

Dyne Therapeutics stock opened at $29.81 on Thursday. Dyne Therapeutics, Inc. has a fifty-two week low of $7.93 and a fifty-two week high of $47.45. The firm’s fifty day moving average price is $33.72 and its 200-day moving average price is $34.94.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DYN. Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Oppenheimer reiterated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.60.

Insiders Place Their Bets

In other Dyne Therapeutics news, CEO John Cox purchased 32,000 shares of the stock in a transaction on Wednesday, September 4th. The stock was acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at approximately $264,320. This trade represents a -100.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, SVP Richard William Scalzo sold 1,390 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the sale, the senior vice president now directly owns 98,568 shares in the company, valued at approximately $3,405,524.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO John Cox bought 32,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. The trade was a -100.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 158,975 shares of company stock valued at $5,693,789 over the last quarter. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.